Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial’s Design – Hagens Berman
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) — Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors…
